8月13日 - ** 周四盘前，AbCellera Biologics（ABCL.O）股价下跌1.3%，报10.22美元，此前该公司定价完成了一笔2亿美元的后续融资
** 这家加拿大生物技术公司周四早些时候宣布 (link)，将以每股9.75美元的价格发行约1740万股股票及预先注资的认股权证，后者可购买最多约310万股股票
** 发行价较该股前一交易日收盘价10.36美元折让5.9%
** 杰富瑞、摩根大通、坎托、瑞银和加拿大帝国商业银行担任联合簿记管理人
** 公司计划将净募集资金用于研发、推进内部产品管线的临床进展（包括其领先的临床项目ABCL635）及其他用途
** 周一，ABCL股价飙升35%，收于9.34美元，此前该公司表示，其更年期治疗药物ABCL635 (link) 在中期试验中减轻了潮热症状
** 本次发行前，公司流通股约为3.066亿股
** 该股年初至今已上涨三倍
** 根据LSEG数据，所有9位覆盖ABCL的分析师均持看涨态度；目标价中位数为14美元
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.